Health ❯ Healthcare ❯ Pharmacology

Drug Development

Combination Therapy Clinical Trials Cancer Therapies GLP-1 Receptor Agonists Baxdrostat BTK Inhibitors Natural Compounds Ambroxol Topical Therapies Targeted Therapies

NEJM Publication Confirms Phase 3 Win for Brepocitinib in Dermatomyositis

The FDA is conducting a Priority Review with a decision expected in the third quarter of 2026.

Anti-Seizure Drug Levetiracetam Blocks Early Alzheimer’s Protein Production, Study Finds

Aloe Vera Compound Beta-Sitosterol Identified as Potential Alzheimer’s Drug Lead in Peer-Reviewed In Silico Study

Repurposed Kidney Drug Triggers Egg Development in Small POI Trial, Science Study Reports

Pooled Data Tie Early AE Management to Greater Zolbetuximab Benefit in Gastric/GEJ Cancer

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

Study Finds CBD–THC Combination Kills Ovarian Cancer Cells in Lab

Ianalumab Plus Eltrombopag Extends Disease Control in Phase 3 ITP Study Published in NEJM

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

Pliant’s PLN-101095 With Keytruda Shows Early Responses in PD-1–Refractory Solid Tumors

Roche Says Breast Cancer Pill Cuts Recurrence in Phase 3 Adjuvant Trial

Bacterial RNA-Repair System Identified as New Target to Boost Common Antibiotics

Oral PCSK9 Pill Enlicitide Cuts LDL Up to 60% in Phase 3 Trial

Nagaland University Study Finds Oral Plant Compound Speeds Diabetic Wound Healing

Eye Drops Pairing Pilocarpine and Diclofenac Improve Near Vision for Up to Two Years

Lung Tumors Reprogram Bone Marrow Progenitors as NRF2 Emerges as a Target

IFITM3 Identified as Key Modulator of Immunotherapy Response in Small Cell Lung Cancer

Jaypirca Delivers Significant PFS Benefit Over Chemoimmunotherapy in First-Line CLL/SLL

Baxdrostat Lowers Blood Pressure in Hard-to-Treat Patients in Phase III Trial

Ionis’ Olezarsen Slashes Triglycerides, Cuts Pancreatitis in Phase 3 Trials